Indeed, although these results may have mainly been driven and biased by the fact that the great majority of luminal-like/HER2-BC patients failed to achieve pCR, available evidence overall highlights the imperative need to further refine the prognostic value of immune infiltrates in this BC subtype, also taking into account the immune biological heterogeneity within luminal-like breast tumors. Here, ERBB2 is linked to breast cancer.